Biliary tract cancer Archives

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

Post author:Jessica Lynn
Post published:February 8, 2024
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Source: Pixabay

ICYMI: Keytruda and Chemo Combination Approved for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Post author:Jessica Lynn
Post published:December 25, 2023
Post category:Biliary tract cancer

Also known as cholangiocarcinoma, biliary tract cancer can be incredibly aggressive. Further, this cancer is often diagnosed in later stages, making it more difficult to treat. The 5-year survival rate currently…

Source: pixabay.com

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:September 11, 2023
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

In the United States, the FDA grants Orphan Drug designation to drugs or biologics that are intended to treat, diagnose, or prevent rare conditions. A rare condition is one…

source: pixabay.com

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

Post author:Rose Duesterwald
Post published:May 23, 2023
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

For patients who were given a diagnosis of advanced, inoperable (unresectable) biliary tract cancer, an article appeared in Healio with some encouraging news. Gemcitabine and cisplatin drugs have…

source: pixabay.com

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:December 19, 2022
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Rare diseases are, by their nature, rare—and because of this, it can be difficult to spur drug development. The FDA worked to overcome this through the creation of the…

source: shutterstock.com

Durvalumab Combo Now FDA-Approved for Biliary Tract Cancer

Post author:Jessica Lynn
Post published:October 25, 2022
Post category:Biliary tract cancer

According to an article in GastroEndo News, first published in Clinical Oncology News, the U.S. Food and Drug Administration (FDA) recently approved a combination of durvalumab and gemcitabine plus…

source: pixabay.com

Devimistat for Biliary Tract Cancer Earns EMA Orphan Drug Designation

Post author:Jessica Lynn
Post published:May 26, 2022
Post category:Biliary tract cancer Cholangiocarcinoma

In Europe, Orphan Drug designation is granted to therapies intended to treat, prevent, or diagnose a rare, life-threatening, or debilitating disease. For the purpose of this status, rare conditions…

source: pixabay.com

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

Post author:James Moore
Post published:April 18, 2022
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

Nelson Ambrogio had always looked up to his older brother, Daniel. He has many positive memories of growing up with him. They both shared a passion for soccer, and Nelson…

source: pixabay.com

ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer

Post author:Jessica Lynn
Post published:March 15, 2022
Post category:Biliary tract cancer Cholangiocarcinoma

In late February 2022, biopharmaceutical company Trascenta Holding Limited ("Trascenta") provided an update on its clinical program for TST001, a monoclonal antibody therapy designed for those with locally advanced or…

jarmoluk / Pixabay

Adding Durvalumab to Chemotherapy Extends Survival in Patients with Advanced Biliary Tract Cancer

Post author:Alyssa Stevens
Post published:March 2, 2022
Post category:Biliary tract cancer Cholangiocarcinoma

According to a recent article, researchers have found that adding durvalumab to chemotherapy treatments results in prolonged survival rates in patients with advanced biliary tract cancer. Biliary Tract Cancer Biliary…

FDA Orphan Drug Designation Given to Biliary Tract Cancer Investigative Therapy

Post author:Trudy Horsting
Post published:February 28, 2022
Post category:Biliary tract cancer

Silmitasertib, an investigative therapy for biliary tract cancer (BTC), has been awarded Orphan Drug Designation by the FDA. Researchers and the regulatory agency are hopeful that this therapy could become…

New Combination Treatment Shown to Increase Survival Rates in Advanced Biliary Tract Cancer

Post author:Trudy Horsting
Post published:February 3, 2022
Post category:Biliary tract cancer

A Phase 3 clinical trial for advanced biliary tract cancer (BTC) has found that there is an improved overall survival rate when patients are given the immunotherapy durvalumab in combination…

Editor’s Choice: Understanding Anxiety, Compassion and Clinical Trials

Post author:Colby Rogers
Post published:July 9, 2021
Post category:Biliary tract cancer

Happy Friday! This week, author Tom Seaman asks: When it comes to anxiety, are you turning your Gizmo into a Gremlin? Also, in our new Compassion Corner series, we examine…

source: pixabay.com

Devimistat for Biliary Cancer Granted Orphan Drug Status

Post author:Jessica Lynn
Post published:July 9, 2021
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

According to MPR, the FDA recently granted Orphan Drug designation to CPI-613 (devimistat), an investigational treatment designed for patients with biliary cancer. Altogether, "biliary cancer" can consist of bile…

stevepb / Pixabay

Truseltiq Approved for Metastatic Cholangiocarcinoma

Post author:Jessica Lynn
Post published:June 21, 2021
Post category:Bile duct cancer Biliary tract cancer Cholangiocarcinoma

In late May 2021, the FDA granted accelerated approval to Truseltiq (infigratinib). As reported by Cure, this therapy is designed for adult patients with unresectable locally advanced, previously treated, or…

source: pixabay.com

New Biomarker Predicts BTC Severity

Post author:Jessica Lynn
Post published:October 7, 2020
Post category:Biliary tract cancer

A biological marker ("biomarker") is a measurable trait or characteristic that can tell researchers something about your body or health. For example, body mass index (BMI) is a common biomarker…

source: pixabay.com

Patients with Biliary Tract Cancer Benefit from Nivolumab-Ipilimumab

Post author:Jessica Lynn
Post published:August 10, 2020
Post category:Biliary tract cancer Rare Disease

Just because we are staying home to avoid COVID-19 doesn't mean the medical field has stopped! In fact, many doctors are more determined than ever to improve patient outcomes.…

source: pixabay.com

Company Announces Completion of Safety Review for Initial Cohort in Cholangiocarcinoma Trial

Post author:James Moore
Post published:December 30, 2019
Post category:Biliary tract cancer Carcinoid Syndrome Rare Disease

According to a story from globenewswire.com, the biopharmaceutical company Lexicon Pharmaceuticals has recently announced that it has completed its safety review of the initial cohort for its phase 2 clinical…

stevepb / Pixabay

Pancreatic Cancer Medication Shows Strong Promise Treating Advanced Biliary Tract Cancers

Post author:Scott Carlson
Post published:July 1, 2019
Post category:Biliary tract cancer Pancreatic Cancer

According to a publication from the Arizona BioIndustry Association, Dr. Rachna Shroff and a team of researchers from the Arizona Cancer Center are studying the use of nab-paclitaxel (a pancreatic…

Updates in Experimental Therapies for Liver Disease

Post author:James Moore
Post published:March 29, 2019
Post category:Autoimmune Hepatitis Biliary tract cancer hepatic porphyria Rare Disease

According to a story from Healio, there are a number of recent reports of progress in the development of treatments for rare forms of liver disease. Many rare liver diseases…

rawpixel / Pixabay

Experimental Treatment for Cholangiocarcinoma Earns Orphan Drug Designation

Post author:James Moore
Post published:March 15, 2019
Post category:Biliary tract cancer

According to a story from BioPortfolio, Imbrium Therapeutics and Mundipharma EDO GmbH recently announced that the US Food and Drug Administration (FDA) has awarded Orphan Drug designation to their experimental…

AndCan / Pixabay

Is This Combination Treatment The Key to Treating Digestive Tract Cancers?

Post author:James Moore
Post published:December 4, 2018
Post category:Biliary tract cancer Small intestine cancer- adult

According to a story from EurekAlert!, the results from a recent Phase 2 clinical trial suggest that a two drug combination could be a useful approach for people with rare,…

Rare Community Profiles: From Stage 4 Cholangiocarcinoma to Cancer-Free in 12 Months: How Hepatic Artery Infusion (HAI) Changed Rick’s Trajectory

ICYMI: Keytruda and Chemo Combination Approved for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

NXP800 for Cholangiocarcinoma Earns Orphan Drug Designation

A Glimmer of Hope for Patients with Advanced Biliary Tract Cancer

ZB131 for Cholangiocarcinoma Earns Orphan Drug Designation

Durvalumab Combo Now FDA-Approved for Biliary Tract Cancer

Devimistat for Biliary Tract Cancer Earns EMA Orphan Drug Designation

Nelson is Running the Boston Marathon in Honor of His Brother, Who Died From Cholangiocarcinoma

ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer

Adding Durvalumab to Chemotherapy Extends Survival in Patients with Advanced Biliary Tract Cancer

FDA Orphan Drug Designation Given to Biliary Tract Cancer Investigative Therapy

New Combination Treatment Shown to Increase Survival Rates in Advanced Biliary Tract Cancer

Editor’s Choice: Understanding Anxiety, Compassion and Clinical Trials

Devimistat for Biliary Cancer Granted Orphan Drug Status

Truseltiq Approved for Metastatic Cholangiocarcinoma

New Biomarker Predicts BTC Severity

Patients with Biliary Tract Cancer Benefit from Nivolumab-Ipilimumab

Company Announces Completion of Safety Review for Initial Cohort in Cholangiocarcinoma Trial

Pancreatic Cancer Medication Shows Strong Promise Treating Advanced Biliary Tract Cancers

Updates in Experimental Therapies for Liver Disease

Experimental Treatment for Cholangiocarcinoma Earns Orphan Drug Designation

Is This Combination Treatment The Key to Treating Digestive Tract Cancers?

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More